BIOMAT Database Logo BIOMAT Database Logo

Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. 1990

A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.

Eight patients with chronic hepatitis B entered a pilot study of gamma interferon and alpha interferon in combination. Gamma interferon alone had minimal inhibitory effects on serum levels of hepatitis B virus as monitored by serum HBV DNA and DNA-polymerase activity. The drug also gave troublesome side effects. In contrast, alpha interferon had more potent inhibitory effects on serum HBV levels and fewer side effects. When combined, the two interferons showed no additive or synergistic effects in inhibiting serum levels of HBV DNA or DNA polymerase. These findings indicate that the addition of gamma interferon to alpha interferon provides no additional antiviral effects but contributes significantly to side effects.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004259 DNA-Directed DNA Polymerase DNA-dependent DNA polymerases found in bacteria, animal and plant cells. During the replication process, these enzymes catalyze the addition of deoxyribonucleotide residues to the end of a DNA strand in the presence of DNA as template-primer. They also possess exonuclease activity and therefore function in DNA repair. DNA Polymerase,DNA Polymerases,DNA-Dependent DNA Polymerases,DNA Polymerase N3,DNA Dependent DNA Polymerases,DNA Directed DNA Polymerase,DNA Polymerase, DNA-Directed,DNA Polymerases, DNA-Dependent,Polymerase N3, DNA,Polymerase, DNA,Polymerase, DNA-Directed DNA,Polymerases, DNA,Polymerases, DNA-Dependent DNA
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
[Antiviral therapy with recombinant alpha-interferon in chronic B virus hepatitis].
June 1990, Revista medica de Chile,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon.
September 1991, Journal of medical virology,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole.
November 1993, Journal of hepatology,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
[Antiviral treatment of chronic active hepatitis B. Combination therapy with beta interferon and recombinant gamma interferon].
July 1988, Fortschritte der Medizin,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
[Therapy of chronic viral hepatitis with recombinant interferon-alpha].
January 1992, Acta medica Austriaca,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: second report.
June 1990, The American journal of gastroenterology,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
Therapy of chronic non-A, non-B hepatitis with alpha interferon. A comparison between natural and recombinant alpha interferon.
December 1993, La Clinica terapeutica,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
Pilot study of recombinant human alpha-interferon for chronic type B hepatitis.
January 1986, Gastroenterology,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
Treatment of chronic delta hepatitis with recombinant human alpha interferon.
January 1987, Progress in clinical and biological research,
A M Di Bisceglie, and V K Rustgi, and C Kassianides, and M Lisker-Melman, and Y Park, and J G Waggoner, and J H Hoofnagle
A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.
November 1993, The American journal of gastroenterology,
Copied contents to your clipboard!